Human Immunodeficiency Virus (HIV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Human Immunodeficiency Virus (HIV) Market Outlook
Thelansis’s “Human Immunodeficiency
Virus (HIV) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Human Immunodeficiency Virus (HIV) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Human
Immunodeficiency Virus (HIV) Overview
Human
immunodeficiency virus (HIV), a lentivirus in the retrovirus family, exhibits
remarkable heterogeneity due to high viral load, rapid turnover rates, an
error-prone reverse transcriptase enzyme, and viral genome recombination within
infected individuals. Retroviruses, characterized by extended incubation
periods, like HIV, gradually lead to clinical latency and eventual onset of
AIDS symptoms, inflicting severe damage on the immune system by exploiting CD4+
cells for replication, ultimately destroying these cells. Zoonotic
transmissions from nonhuman primates to humans have spawned diverse HIV
lineages: HIV-1 groups M, N, O, and P and HIV-2 groups A-H. HIV-1 group M,
responsible for the global pandemic, shares a direct but independent origin
from SIVcpz in chimpanzees. For treating HIV infection, the FDA has approved
over two dozen antiretroviral drugs, which can be categorized into six groups:
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside
Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase
Inhibitors, Fusion Inhibitors, Capsid Inhibitor, gp120 Attachment Inhibitor,
and CCR5 Antagonist.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment